Organoid therapeutics help regenerate human organ analogs by culturing cells in three dimensions and transplanting them into damaged parts. They are characterized by a higher engraftment rate and persistence than two-dimensional stem cell therapies.

To expand and upgrade its technology, the company is pushing to fuse organoids and artificial intelligence (AI) technology to automate production, establish standards and test methods, and develop solutions to optimize mass production.